Michael Gilman is a prominent figure in the biotechnology industry with a wealth of experience in executive leadership roles.

Currently serving as the Chief Executive Officer at Arrakis Therapeutics, Michael has demonstrated his strategic vision and business acumen in steering the company towards success.

Prior to his role at Arrakis Therapeutics, he held the position of Chief Executive Officer at Obsidian Therapeutics, showcasing his versatility and adaptability in managing different organizations.

With a strong entrepreneurial spirit, Michael founded and led multiple companies, including Padlock Therapeutics and Stromedix, Inc., where he played a pivotal role in driving innovation and growth.

His tenure at Biogen Idec, where he served as Senior Vice President of the Early Stage Pipeline and later as Executive Vice President of Research, further solidified his reputation as a leader in the field of biotechnology.

Michael's extensive experience also includes holding the role of Executive Vice President and Chief Scientific Officer at ARIAD Pharmaceuticals, where he made significant contributions to the company's research and development efforts.

His scientific expertise was honed during his time as a Senior Staff Scientist at Cold Spring Harbor Laboratory and as a Postdoctoral Fellow at Whitehead Institute, reflecting his deep understanding of molecular biology and drug discovery.

Throughout his career, Michael Gilman has consistently demonstrated his commitment to advancing the biotechnology sector through innovative strategies and leadership initiatives.